Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
14 févr. 2019 09h00 HE
|
H. Lundbeck A/S
The efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with bipolar I disorder was investigated in two three-week, double-blind,...
Annual Report 2018 for H.Lundbeck A/S
05 févr. 2019 01h52 HE
|
H. Lundbeck A/S
Annual Report 2018 for H.Lundbeck A/S
Attachment
ANNUALREPORT2018
...
Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018
05 févr. 2019 01h40 HE
|
H. Lundbeck A/S
Financial report for the period 1 January to 31 December 2018 Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018 HIGHLIGHTS Revenue reached...
Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
22 janv. 2019 00h32 HE
|
H. Lundbeck A/S
Valby, Denmark, 22 January 2019 - H. Lundbeck A/S (Lundbeck) today announced that Dr. Johan Luthman has been appointed Executive Vice President and Head of Research & Development in Lundbeck....
Dr. Johan Luthman udnævnt koncerndirektør for forskning og udvikling hos Lundbeck
22 janv. 2019 00h32 HE
|
H. Lundbeck A/S
Valby, Danmark, 22 januar 2019 - H. Lundbeck A/S (Lundbeck) annoncerede i dag, at Dr. Johan Luthman er blevet udnævnt som Executive Vice President og koncerndirektør for forskning og udvikling hos...
Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development
04 déc. 2018 03h38 HE
|
H. Lundbeck A/S
Valby, Denmark, 4 December 2018 - H. Lundbeck A/S (Lundbeck) today announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19...
Anders Gersel Pedersen, koncerndirektør for forskning og udvikling hos Lundbeck, går på pension
04 déc. 2018 03h38 HE
|
H. Lundbeck A/S
Valby, Danmark, 4. december 2018 - H. Lundbeck A/S (Lundbeck) annoncerede i dag, at Anders Gersel Pedersen, koncerndirektør for forskning og udvikling, går på pension efter 19 år i firmaet. Anders...
Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
30 nov. 2018 03h17 HE
|
H. Lundbeck A/S
Valby, Nov. 30, 2018 (GLOBE NEWSWIRE) -- The combination treatment arm of brexpiprazole and sertraline demonstrated improvement in symptoms of PTSD versus placebo (p<0.01) on the primary...
Lundbeck og Otsuka rapporterer positive fase II-data for kombinationsbehandling med brexpiprazol og sertralin til behandling af post-traumatisk stress syndrom (PTSD)
30 nov. 2018 03h17 HE
|
H. Lundbeck A/S
Valby, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Kombinationsbehandlingsarmen med brexpiprazol og sertralin udviste forbedring af symptomer i PTSD sammenlignet med placebo (p<0.01) på det primære...
Kapitalforhøjelse i Lundbeck med 6.574 aktier (0,0033 % af udestående aktier) som følge af warrant-program for medarbejdere
20 nov. 2018 05h51 HE
|
H. Lundbeck A/S
Valby, Nov. 20, 2018 (GLOBE NEWSWIRE) -- - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort beslutningen om at udvide aktiekapitalen med DKK 32.870 som følge af udnyttelsen af...